Latest Homologous recombination Stories
An international team of scientists led by UC Davis researchers has discovered that DNA repair in cancer cells is not a one-way street as previously believed.
In children with genomic disorders, often a gamete – egg or sperm – has gone disastrously awry with either a duplication or deletion of genetic material that results in physical and neurological problems for the subsequent child.
Scientists have uncovered an important clue to one of the mechanisms underlying cancer cell immortality.
DNA is under constant attack, from internal factors like free radicals and external ones like ionizing radiation.
DNA's role as the master blueprint of the cell means that even small sequence changes can have catastrophic consequences.
PARIS, April 4, 2011 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the genome engineering specialist, has announced today that it has signed a license agreement with a pharmaceutical company covering certain uses of its homologous recombination technology patents and patent applications, in the oncology therapeutic field. This agreement has triggered an immediate payment of euro 3M ($4.2M) to Cellectis. Further details of the arrangement have not been disclosed.
DNA was originally thought to have a single function: to help cells make the proteins they need.
Scientists have discovered how a network of repair proteins enables bacteria to prioritise the repair of the most heavily used regions of the DNA molecules that carry the instructions necessary for living cells to function.
An Iowa State University team of researchers has developed a type of hybrid proteins that can make double-strand DNA breaks at specific sites in living cells, possibly leading to better gene replacement and gene editing therapies.
A team of investigators led by a physician-scientist at The University of Texas MD Anderson Cancer Center has shown for the first time that the small protein SUMO can team up with the replication protein A (RPA) complex to facilitate DNA repair.